Introducing the SLCO1B1 c.521T>C RealFast™ Assay – the fast and accurate PCR test for detecting a genetic variant responsible for simvastatin-induced myopathy, a severe side effect of statin treatment.

Simvastatin is a widely prescribed statin for reducing LDL cholesterol levels, but its dose-dependent adverse events, including myopathy and rhabdomyolysis, are concerning. The c.521T>C variant of the SLCO1B1 gene affects the hepatic uptake and metabolism of statins, leading to increased risk of simvastatin-induced myopathy in patients carrying the c.521C allele.

The SLCO1B1 c.521T>C RealFast™ Assay identifies the c.521T>C genotype in a human DNA extract, enabling personalized dose adjustment of simvastatin according to CPIC guidelines. By avoiding the risk of simvastatin-induced myopathy, patients can benefit from the lipid-lowering effects of statin therapy without experiencing severe side effects.

Trust in Viennalab’s expertise and experience in molecular diagnostics to provide you with reliable and easy-to-use results for your laboratory workflow. Improve patient safety and reduce the risk of statin-induced myopathy associated with empirical dosing – add the SLCO1B1 c.521T>C RealFast™ Assay to your laboratory today.